Fate Therapeutics Financial Results
Fate Therapeutics reported third-quarter 2026 financial results, highlighting a cash position of $139.1 million and a runway extending into mid-2028. The company is advancing its RECLAIM-LN Phase 2 trial for FT819 in lupus nephritis and recently received a $15 million grant from the California Institute for Regenerative Medicine (CIRM) to support the program.
- Term
- Q3 2026
“The third quarter was defined by steady execution across our portfolio, bringing us closer to our goal of delivering off-the-shelf, master cell bank derived cell therapies to the patients who need them most.”
Bob Valamehr, Ph.D., MBA, President and Chief Executive Officer
“Our progress this year, together with continued extension of our cash runway, positions us well for important milestones ahead, and we remain focused on execution as we work to deliver across multiple fronts in 2027.”
Bob Valamehr, Ph.D., MBA, President and Chief Executive Officer